171 related articles for article (PubMed ID: 38043731)
41. Identification and validation of microRNAs directly regulating the UDP-glucuronosyltransferase 1A subfamily enzymes by a functional genomics approach.
Papageorgiou I; Court MH
Biochem Pharmacol; 2017 Aug; 137():93-106. PubMed ID: 28433553
[TBL] [Abstract][Full Text] [Related]
42. Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans.
Kato Y; Ikushiro S; Emi Y; Tamaki S; Suzuki H; Sakaki T; Yamada S; Degawa M
Drug Metab Dispos; 2008 Jan; 36(1):51-5. PubMed ID: 17908920
[TBL] [Abstract][Full Text] [Related]
43. Transcriptome association analysis identifies miR-375 as a major determinant of variable acetaminophen glucuronidation by human liver.
Papageorgiou I; Freytsis M; Court MH
Biochem Pharmacol; 2016 Oct; 117():78-87. PubMed ID: 27531059
[TBL] [Abstract][Full Text] [Related]
44. Structure-inhibition relationship of podophyllotoxin (PT) analogues towards UDP-glucuronosyltransferase (UGT) isoforms.
Qi JQ; Cao YF; Sun XY; Hong M; Fang ZZ; Meng DL; Sun DX
Pharmazie; 2015 Apr; 70(4):239-43. PubMed ID: 26012253
[TBL] [Abstract][Full Text] [Related]
45. UDP-glucuronosyltransferase 1a enzymes are present and active in the mouse blastocyst.
Collier AC; Yamauchi Y; Sato BL; Rougée LR; Ward MA
Drug Metab Dispos; 2014 Nov; 42(11):1921-5. PubMed ID: 25200869
[TBL] [Abstract][Full Text] [Related]
46. Comparison of Sweated and Non-Sweated Ethanol Extracts of
Liu J; Shi Y; Wu C; Hong B; Peng D; Yu N; Wang G; Wang L; Chen W
Curr Drug Metab; 2022; 23(6):473-483. PubMed ID: 35585828
[TBL] [Abstract][Full Text] [Related]
47. A broad-spectrum substrate for the human UDP-glucuronosyltransferases and its use for investigating glucuronidation inhibitors.
Zhou QH; Qin WW; Finel M; He QQ; Tu DZ; Wang CR; Ge GB
Int J Biol Macromol; 2021 Jun; 180():252-261. PubMed ID: 33741369
[TBL] [Abstract][Full Text] [Related]
48. Enantioselective inhibition of carprofen towards UDP-glucuronosyltransferase (UGT) 2B7.
Fang ZZ; Wang H; Cao YF; Sun DX; Wang LX; Hong M; Huang T; Chen JX; Zeng J
Chirality; 2015 Mar; 27(3):189-93. PubMed ID: 25502512
[TBL] [Abstract][Full Text] [Related]
49. Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7.
Tsoutsikos P; Miners JO; Stapleton A; Thomas A; Sallustio BC; Knights KM
Biochem Pharmacol; 2004 Jan; 67(1):191-9. PubMed ID: 14667942
[TBL] [Abstract][Full Text] [Related]
50. Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid.
Mackenzie PI
Ther Drug Monit; 2000 Feb; 22(1):10-3. PubMed ID: 10688250
[TBL] [Abstract][Full Text] [Related]
51. Inhibition potential of UDP-glucuronosyltransferases (Ugts) 1A isoforms by the analogue of resveratrol, bakuchiol.
Dong DG; Zhang Y; Zhang SL; Lv J; Guo EM; Fang ZZ; Cao YF
Pharmazie; 2014 Jan; 69(1):60-3. PubMed ID: 24601226
[TBL] [Abstract][Full Text] [Related]
52. Drug interaction study of natural steroids from herbs specifically toward human UDP-glucuronosyltransferase (UGT) 1A4 and their quantitative structure activity relationship (QSAR) analysis for prediction.
Xu M; Dong P; Tian X; Wang C; Huo X; Zhang B; Wu L; Deng S; Ma X
Pharmacol Res; 2016 Aug; 110():139-150. PubMed ID: 27208893
[TBL] [Abstract][Full Text] [Related]
53. In Vitro Inhibition of Human UDP-Glucuronosyl-Transferase (UGT) Isoforms by Astaxanthin, β-Cryptoxanthin, Canthaxanthin, Lutein, and Zeaxanthin: Prediction of in Vivo Dietary Supplement-Drug Interactions.
Zheng YF; Min JS; Kim D; Park JB; Choi SW; Lee ES; Na K; Bae SK
Molecules; 2016 Aug; 21(8):. PubMed ID: 27529203
[TBL] [Abstract][Full Text] [Related]
54. The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure.
Court MH; Freytsis M; Wang X; Peter I; Guillemette C; Hazarika S; Duan SX; Greenblatt DJ; Lee WM;
J Pharmacol Exp Ther; 2013 May; 345(2):297-307. PubMed ID: 23408116
[TBL] [Abstract][Full Text] [Related]
55. Alternatively spliced products of the UGT1A gene interact with the enzymatically active proteins to inhibit glucuronosyltransferase activity in vitro.
Bellemare J; Rouleau M; Girard H; Harvey M; Guillemette C
Drug Metab Dispos; 2010 Oct; 38(10):1785-9. PubMed ID: 20610558
[TBL] [Abstract][Full Text] [Related]
56. N-glucuronidation of the platelet-derived growth factor receptor tyrosine kinase inhibitor 6,7-(dimethoxy-2,4-dihydroindeno[1,2-C]pyrazol-3-yl)-(3-fluoro-phenyl)-amine by human UDP-glucuronosyltransferases.
Yan Z; Caldwell GW; Gauthier D; Leo GC; Mei J; Ho CY; Jones WJ; Masucci JA; Tuman RW; Galemmo RA; Johnson DL
Drug Metab Dispos; 2006 May; 34(5):748-55. PubMed ID: 16455802
[TBL] [Abstract][Full Text] [Related]
57. [Induction of uridine 5'-diphosphate-glucuronosyltransferase gene expression by sulforaphane and its mechanism: experimental study in human colon cancel cells].
Wang M; Li YQ; Zhong N; Chen J; Xu XQ; Yuan MB
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(12):819-24. PubMed ID: 15949398
[TBL] [Abstract][Full Text] [Related]
58. Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation.
Tagawa K; Maruo Y; Mimura Y; Ikushiro S
Toxicol Mech Methods; 2023 Mar; 33(3):197-205. PubMed ID: 35930428
[TBL] [Abstract][Full Text] [Related]
59. In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.
House L; Ramirez J; Seminerio M; Mirkov S; Ratain MJ
Xenobiotica; 2015; 45(11):990-8. PubMed ID: 26053558
[TBL] [Abstract][Full Text] [Related]
60. Inhibitory effects of uridine diphosphate on UDP-glucuronosyltransferase.
Yokota H; Ando F; Iwano H; Yuasa A
Life Sci; 1998; 63(19):1693-9. PubMed ID: 9806225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
